| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $10,150,648 | 25 | 100 |
| SULIMAN SHEHNAAZ | director | 0 | $0 | 2 | $327,234 | $-327,234 |
| Teichmann Sarah A. | director | 0 | $0 | 3 | $579,387 | $-579,387 |
| STUELPNAGEL JOHN R | director | 0 | $0 | 1 | $1.16M | $-1.16M |
| Hindson Benjamin J. | See Remarks | 0 | $0 | 4 | $1.46M | $-1.46M |
| Taich Adam | Chief Financial Officer | 0 | $0 | 4 | $1.84M | $-1.84M |
| Saxonov Serge | Chief Executive Officer | 0 | $0 | 11 | $4.79M | $-4.79M |
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Over the last 12 months, insiders at 10x Genomics, Inc. have bought $0 and sold $10.15M worth of 10x Genomics, Inc. stock.
On average, over the past 5 years, insiders at 10x Genomics, Inc. have bought $229,183 and sold $17.09M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $445,572 was made by MATEO ALAN (director) on 2025‑02‑21.
| 2026-08-26 | Sale | Saxonov Serge | Chief Executive Officer | 10,486 0.0082% | $63.69 | $667,901 | -2.66% | |
| 2026-08-24 | Sale | Saxonov Serge | Chief Executive Officer | 18,545 0.0141% | $63.02 | $1.17M | -1.36% | |
| 2026-08-24 | Sale | Hindson Benjamin J. | See Remarks | 13,818 0.0105% | $63.02 | $870,860 | -1.36% | |
| 2026-08-24 | Sale | Taich Adam | Chief Financial Officer | 17,166 0.013% | $63.02 | $1.08M | -1.36% | |
| 2026-08-24 | Sale | SULIMAN SHEHNAAZ | director | 2,207 0.0017% | $63.65 | $140,478 | -1.36% | |
| 2026-08-14 | Sale | Teichmann Sarah A. | director | 2,273 0.0018% | $57.15 | $129,902 | +12.20% | |
| 2026-08-13 | Sale | Teichmann Sarah A. | director | 5,278 0.004% | $57.29 | $302,377 | +7.74% | |
| 2026-08-11 | Sale | STUELPNAGEL JOHN R | director | 20,000 0.0156% | $57.75 | $1.16M | +6.79% | |
| 2026-06-22 | Sale | Saxonov Serge | Chief Executive Officer | 30,000 0.0247% | $34.44 | $1.03M | +43.40% | |
| 2026-06-16 | Sale | SULIMAN SHEHNAAZ | director | 5,723 0.0046% | $32.63 | $186,756 | +48.19% | |
| 2026-05-26 | Sale | Saxonov Serge | Chief Executive Officer | 10,718 0.0082% | $24.71 | $264,833 | +85.52% | |
| 2026-05-22 | Sale | Saxonov Serge | Chief Executive Officer | 18,175 0.0148% | $24.44 | $444,224 | +92.57% | |
| 2026-05-22 | Sale | Hindson Benjamin J. | See Remarks | 11,595 0.0094% | $24.44 | $283,399 | +92.57% | |
| 2026-05-22 | Sale | Taich Adam | Chief Financial Officer | 15,098 0.0123% | $24.44 | $369,018 | +92.57% | |
| 2026-04-14 | Sale | Saxonov Serge | Chief Executive Officer | 5,000 0.0042% | $24.56 | $122,784 | +48.19% | |
| 2026-03-24 | Sale | Saxonov Serge | Chief Executive Officer | 5,000 0.0039% | $19.52 | $97,612 | +62.34% | |
| 2026-03-23 | Sale | Saxonov Serge | Chief Executive Officer | 10,000 0.0078% | $19.13 | $191,297 | +67.95% | |
| 2026-03-02 | Sale | Saxonov Serge | Chief Executive Officer | 16,152 0.0125% | $22.73 | $367,097 | +26.10% | |
| 2026-02-25 | Sale | Teichmann Sarah A. | director | 7,579 0.0059% | $19.41 | $147,108 | +47.91% | |
| 2026-02-23 | Sale | Saxonov Serge | Chief Executive Officer | 9,632 0.0074% | $18.58 | $178,928 | +53.23% |
| Saxonov Serge | Chief Executive Officer | 1075349 0.847% | $67.37M | 0 | 72 | |
| Hindson Benjamin J. | See Remarks | 488182 0.3845% | $30.58M | 0 | 49 | |
| Taich Adam | Chief Financial Officer | 362732 0.2857% | $22.73M | 0 | 6 | |
| STUELPNAGEL JOHN R | director | 348436 0.2745% | $21.83M | 0 | 39 | |
| SULIMAN SHEHNAAZ | director | 29515 0.0232% | $1.85M | 0 | 2 | |
| Teichmann Sarah A. | director | 28058 0.0221% | $1.76M | 0 | 3 | |
| Paladin Capital Management, LLC | 10 percent owner | 5617583 4.4248% | $351.94M | 0 | 2 | |
| Foresite Capital Management I, LLC | 10 percent owner | 2350000 1.851% | $147.23M | 1 | 2 | +46.56% |
| ROBERTS BRYAN E | director | 1287825 1.0144% | $80.68M | 1 | 1 | +41.14% |
| Venrock Associates VI, L.P. | 10 percent owner | 1287825 1.0144% | $80.68M | 0 | 1 | |
| Mammen Mathai | director | 169745 0.1337% | $10.63M | 0 | 1 | |
| McAnear Justin J. | Former Chief Financial Officer | 143242 0.1128% | $8.97M | 1 | 38 | <0.0001% |
| CRUTCHFIELD BRADFORD | Chief Commercial Officer | 97237 0.0766% | $6.09M | 1 | 31 | <0.0001% |
| Wilbur James | Chief Commercial Officer | 83342 0.0656% | $5.22M | 0 | 4 | |
| MATEO ALAN | director | 61691 0.0486% | $3.86M | 1 | 0 | +17.2% |
| Kosaraju Sridhar | director | 3000 0.0024% | $187,950.00 | 0 | 10 |
| Increased Positions | 172 | +46.74% | 18M | +14.26% |
| Decreased Positions | 157 | -42.66% | 18M | -14.67% |
| New Positions | 63 | New | 6M | New |
| Sold Out Positions | 59 | Sold Out | 3M | Sold Out |
| Total Postitions | 383 | +4.08% | 123M | -0.41% |
| Vanguard Group Inc | $220,619.00 | 11.44% | 13.27M | +834,272 | +6.71% | 2025-09-30 |
| Ark Investment Management Llc | $197,569.00 | 10.25% | 11.89M | -2M | -14.43% | 2025-09-30 |
| Blackrock, Inc. | $157,227.00 | 8.15% | 9.46M | +25,613 | +0.27% | 2025-09-30 |
| Fmr Llc | $140,572.00 | 7.29% | 8.46M | -538,403 | -5.99% | 2025-09-30 |
| Millennium Management Llc | $90,379.00 | 4.69% | 5.44M | +3M | +88.57% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $89,436.00 | 4.64% | 5.38M | -636,744 | -10.58% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $89,364.00 | 4.64% | 5.38M | -632,770 | -10.53% | 2025-09-30 |
| Wellington Management Group Llp | $71,227.00 | 3.7% | 4.29M | +2M | +126.6% | 2025-09-30 |
| Quantinno Capital Management Lp | $58,045.00 | 3.01% | 3.49M | +1M | +56.37% | 2025-09-30 |
| Bank Of America Corp /De/ | $56,729.00 | 2.94% | 3.41M | +389,797 | +12.89% | 2025-09-30 |